New European guidelines for the management of patients with precancerous changes in the stomach
https://doi.org/10.21518/2079-701X-2019-3-44-47
Abstract
Aim of the review: to analyze the current aspects of the management of patients with precancerous changes in the stomach, as outlined in the new MAPS II European recommendations.
Basic provisions. For qualified diagnosis of precancerous changes in the stomach it is necessary to use modern endoscopic and morphological methods. Timely detection of atrophy, metaplasia and dysplasia significantly increases the effectiveness of gastric cancer prevention. Eradication of Helicobacter pylori infection is an important principle in the management of patients with precancerous changes in the stomach.
Conclusion. According to European recommendations, timely diagnosis, adequate treatment and follow-up of patients with precancerous gastric changes play an important role in the prevention of stomach cancer. The application of such principles in daily clinical practice will allow standardization of the approach to the management of patients with pre-tumor pathology.
Keywords
About the Authors
V. V. Tsukanov
Research Institute for Medical Problems in the North - Division of Federal Research Center «Krasnoyarsk Scientific Center of the Siberian Branch of the RAS»
Russian Federation
Russian Federation
Dr. of Sci. (Med), Professor, Head of the Clinical Department of Pathology of the Digestive System,
660022, Krasnoyarsk, 3 «Г» Partizana Zheleznyaka Street
A. V. Vasyutin
Research Institute for Medical Problems in the North - Division of Federal Research Center «Krasnoyarsk Scientific Center of the Siberian Branch of the RAS»
Russian Federation
Russian Federation
Cand. of Sci. (Med.), Senior Researcher at the Clinical Department of Pathology of the Digestive System in Adults and Children,
660022, Krasnoyarsk, 3 «Г» Partizana Zheleznyaka Street
J. L. Tonkih
Research Institute for Medical Problems in the North - Division of Federal Research Center «Krasnoyarsk Scientific Center of the Siberian Branch of the RAS»
Russian Federation
Russian Federation
Cand. of Sci. (Med.), Leading Researcher of the Clinical Department of Pathology of the Digestive System in Adults and Children,
660022, Krasnoyarsk, 3 «Г» Partizana Zheleznyaka Street
O. V. Peretyatko
Research Institute for Medical Problems in the North - Division of Federal Research Center «Krasnoyarsk Scientific Center of the Siberian Branch of the RAS»
Russian Federation
Russian Federation
Cand. of Sci. (Med.), Researcher of the Clinical Department of Pathology of the Digestive System in Adults and Children,
660022, Krasnoyarsk, 3 «Г» Partizana Zheleznyaka Street
References
1. Rugge M., Genta R.M., Graham D.Y., Di Mario F., Vaz Coelho L.G., Kim N. et al. Chronicles of a cancer foretold: 35 years of gastric cancer risk assessment. Gut. 2016;65(5):721-725.
2. Liu H., Li P.W., Yang W.Q., Mi H., Pan J.L., Huang Y.C. et al. Identification of non-invasive biomarkers for chronic atrophic gastritis from serum exosomal microRNAs. BMC Cancer. 2019;19(1):129.
3. Tsukanov V.V., Amelchugova O.S., Kasparov E.V., Butorin N.N., Vasyutin A.V., Tonkikh Y.L., Tretyakova O.V. The role of Helicobacter pylori eradication in the prevention of stomach cancer. Therapist Arch. [Terapevt. arh.]. 2014;86(8):124-127. (In Russ.)
4. Wang Z., Graham D.Y., Khan A., Balakrishnan M., Abrams H.R., El-Serag H.B., Thrift A.P. Incidence of gastric cancer in the USA during 1999 to 2013: a 50-state analysis. Int J Epidemiol. 2018ю [Epub ahead of print]. doi: 10.1093/ije/dyy055.
5. Pimentel-Nunes Pю, Libânio Dю, Marcos-Pinto Rю, Areia Mю, Leja Mю, Esposito Gю et al. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019. Endoscopyю 2019;51(4):365-388.
6. Malfertheiner P., Megraud F., O’Morain C.A., Gisbert J.P., Kuipers E.J., Axon A.T. et al. Management of Helicobacter pylori infectionthe Maastricht V/Florence Consensus Report. Gut. 2017;66(1):6-30.
7. Sugano K., Tack J., Kuipers E.J., Graham DY, El-Omar EM, Miura S et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64(9):1353-1367.
8. Kapadia C.R. Gastric atrophy, metaplasia and dysplasia: a clinical perspective. J Clin Gastroenterol. 2003;36(5 Suppl):S29-S36.
9. Correa P. Gastric cancer: overview. Gastroenterol Clin North Am. 2013;42(2):211-217.
10. Zhao Z., Yin Z., Wang S., Wang J., Bai B., Qiu Z., Zhao Q. Meta-analysis: The diagnostic efficacy of chromoendoscopy for early gastric cancer and premalignant gastric lesions. J Gastroenterol Hepatol, 2016;31(9):1539-1545.
11. Rugge M., Correa P., Di Mario F., El-Omar E., Fiocca R., Geboes K. et al. OLGA staging for gastritis: a tutorial. Dig Liver Dis, 2008, 40(8): 650-658.
12. Capelle L.G., de Vries A.C., Haringsma J., Ter Borg F., de Vries R.A., Bruno M.J. et al. The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. Gastrointest Endosc. 2010;71(7):1150-1158.
13. Dinis-Ribeiro M., Areia M., de Vries A.C., MarcosPinto R., Monteiro-Soares M., O’Connor A. et al. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). Endoscopy. 2012;44(1):74-94.
14. Huang Y.K., Yu J.C., Kang W.M., Ma Z.Q., Ye X., Tian S.B., Yan C. Significance of Serum Pepsinogens as a Biomarker for Gastric Cancer and Atrophic Gastritis Screening: A Systematic Review and Meta-Analysis. PLoS One. 2015;10(11):e0142080.
15. Mera R.M., Bravo L.E., Camargo M.C., Bravo J.C., Delgado A.G., Romero-Gallo J. et al. Dynamics of Helicobacter pylori infection as a determinant of progression of gastric precancerous lesions: 16-year follow-up of an eradication trial. Gut. 2018;67(7):1239-1246.
16. Marcos-Pinto R., Dinis-Ribeiro M., Carneiro F., Wen X., Lopes C., Figueiredo C. et al. Firstdegree relatives of early-onset gastric cancer patients show a high risk for gastric cancer: phenotype and genotype profile. Virchows Arch.2013;463(3):391-399.
17. Chen H.N., Wang Z., Li X., Zhou Z.G. Helicobacter pylori eradication cannot reduce the risk of gastric cancer in patients with intestinal metaplasia and dysplasia: evidence from a meta-analysis. Gastric Cancer. 2016;19(1):166-175.
18. Rokkas T., Rokka A., Portincasa P. A systematic review and meta-analysis of the role of Helicobacter pylori eradication in preventing gastric cancer. Ann Gastroenterol. 2017;30(4):414-423.
19. Tsukanov V.V., Kasparov E.V., Tonkikh J.L., Shtygasheva O.V., Butorin N.N., Amelchugova O.S. et al. Peptic Ulcer Disease and Helicobacter pylori Infection in Different Siberian Ethnicities. Helicobacter. 2017;22(1):e12322.
20. Choi I.J., Kook M.C., Kim Y.I., Cho S.J., Lee J.Y., Kim C.G., Park B., Nam B.H. Helicobacter pylori Therapy for the Prevention of Metachronous Gastric Cancer. N Engl J Med. 2018;378(12):1085-1095.
21. O’Morain N.R., Dore M.P., O’Connor A.J.P., Gisbert J.P., O’Morain C.A. Treatment of Helicobacter pylori infection in 2018. Helicobacter. 2018;23(Suppl 1):e12519.
22. Bordin D.S., Embutnieks Yu.V., Vologzhanina L.G., Ilchishina T.A., Voynovan I.N., Sarsenbaeva A.S., etc. European register of Helicobacter pylori (Hp-EuReg): how clinical practice in Russia changed from 2013 to 2018. Therapeut. Arch. [Terapevt. arh.]. 2019;91(2):8-24. (In Russ.)
23. Ivashkin V.T., Maev I.V., Lapina T.L., Sheptulin A.A., Trukhmanov A.S., Baranskaya E.K. et al. Clinical recommendations of the Russian Gastroenterological Association on diagnosis and treatment of Helicobacter pylori infection in adults. Ros. journ. of gastroenterology, hepatology, coloproctology [Ros. zhurn. gastrojenterologii, gepatologii, koloproktologii]. 2018;1:55-70. (In Russ.)
24. McNicholl A.G., Linares P.M., Nyssen O.P., Calvet X., Gisbert J.P. Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther. 2012;36(5):414-425.
25. Graham D.Y. Helicobacter pylori update: gastric cancer, reliable therapy, and possible benefits. Gastroenterology. 2015;148(4):719-731.
26. McMahon B.J., Bruce M.G., Koch A., Goodman K.J., Tsukanov V., Mulvad G. et al. The diagnosis and treatment of Helicobacter pylori infection in Arctic regions with a high prevalence of infection: Expert Commentary. Epidemiol Infect. 2016;144(2):225-33.
Review
For citations:
Tsukanov VV, Vasyutin AV, Tonkih JL, Peretyatko OV. New European guidelines for the management of patients with precancerous changes in the stomach. Meditsinskiy sovet = Medical Council. 2019;(3):44-47. (In Russ.) https://doi.org/10.21518/2079-701X-2019-3-44-47
Views:
2008
Email this article 